Ignite Creation Date:
2025-12-25 @ 12:22 AM
Ignite Modification Date:
2026-01-01 @ 7:29 PM
Study NCT ID:
NCT05064358
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-07
First Post:
2021-09-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
Sponsor:
GlaxoSmithKline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-03
Start Date Type:
ACTUAL
Primary Completion Date:
2024-08-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-01-30
Completion Date Type:
ESTIMATED
First Submit Date:
2021-09-22
First Submit QC Date:
None
Study First Post Date:
2021-10-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-08-06
Results First Submit QC Date:
None
Results First Post Date:
2025-10-07
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-18
Last Update Post Date:
2025-10-07
Last Update Post Date Type:
ESTIMATED